Crossover study of 99mTc-TRODAT-1 SPECT and 18F-FDOPA PET in Parkinson's disease patients

Journal of Nuclear Medicine

Volumn 44, Issue 7, 2003, Pages 999-1005

  Huang, Wen Sheng ^a   Chiang, Yung Hsiao ^a   Lin, Jiann Chyun ^a   Chou, Yuan Hwa ^a   Cheng, Cheng Yi ^a   Liu, Ren Shyan ^b  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

6 18F fluoro L dopa PET; 99mTc TRODAT 1 SPECT; Parkinson's disease

Indexed keywords

6 FLUORODOPA F 18; [2 [[2 [[[3 (4 CHLOROPHENYL) 8 METHYL 8 AZABICYCLO[3.2.1]OCT 2 YL]METHYL](2 MERCAPTOETHYL)AMINO]ETHYL]AMINO]ETHANETHIOLATO]OXOTECHNETIUM TC 99M; CARBIDOPA; DIAGNOSTIC AGENT; DOPA; DRUG DERIVATIVE; FLUORODOPA F 18; RADIOPHARMACEUTICAL AGENT; TECHNETIUM COMPLEX; TECHNETIUM TC 99M TRODAT 1; TECHNETIUM TC 99M TRODAT-1; TROPANE DERIVATIVE;

ARTICLE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DIAGNOSTIC IMAGING; DRUG UPTAKE; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; LINEAR REGRESSION ANALYSIS; MEDICAL EXAMINATION; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; SAMPLE SIZE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; WHOLE BODY AUTORADIOGRAPHY; AGED; CLINICAL TRIAL; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CROSSOVER PROCEDURE; FEMALE; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; REFERENCE VALUE; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION;

AGED; CORPUS STRIATUM; CROSS-OVER STUDIES; DIHYDROXYPHENYLALANINE; FEMALE; HUMANS; MALE; MIDDLE AGED; ORGANOTECHNETIUM COMPOUNDS; PARKINSON DISEASE; PUTAMEN; RADIOPHARMACEUTICALS; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 0042388390     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999;56:33-39.
2. Hughes AJ, Daniel SE, Kilford L, Lees AJ. The accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study. J Neurol Neurosurg Psychiatry. 1992;55:181-184
3. Agid Y. Parkinson's disease: pathophysiology. Lancet 1991;337:1321-1324.
4. Brooks DJ. PET studies on the early and differential diagnosis of Parkinson's disease. Neurology. 1993;43(suppl 6):S6-S16.
5. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in striatum of patients with idiopathic Parkinson's disease. N Engl J Med. 1988; 876:876-880.
6. Uhl GR. Neurotransmitter transporters (plus): a promising new gene family. Trends Neurosci. 1992;15:265-268.
7. Nirenberg MJ, Vaughan RA, Uhl GR, Kuhar MJ, Pickel VM. The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons. J Neurosci. 1996;16:436-447
8. 99mTc]TRODAT-1 in hemi-parkinsonism rat brain. Nucl Med Biol. 2001; 28:923-928.
9. Wilson JM, Levey AI, Rajput A, et al. Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease. Neurology. 1996;47:718-726.
10. 99mTc]TRODAT-1 to dopamine transporter in patients with Parkinson's disease and in healthy volunteers. J Nucl Med. 2000;41:584-589.
11. Niznik HB, Fogel EF, Fassos FF, Seeman P. The dopamine transporter is absent in Parkinsonian putamen and reduced in the caudate nucleus. J Neurochem. 1991;56:192-198.
12. Booij J, Tissingh G, Winogrodzka A, van Royen EZ. Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism. Eur J Nucl Med. 1999;26:171-182
13. Innis RB, Seibyl JB, Scanley BE, et al. Single photon computed imaging demonstrates loss of striatal dopamine transporters in Parkinson's disease. Proc Natl Acad Sci USA 1993;90:11965-11969.
14. 123I]β-CIT SPECT striatal uptake correlates with symptom seventy in Parkinson's disease Ann Neurol 1995;38:589-598
15. Parkinson Study Group. A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism Neurology. 2000;55:1540-1547.
16. 99mTc [abstract]. J Nucl Med. 1997;38(suppl):100P.
17. 99mTc] SPECT imaging agent which targets the dopamine transporter in primate brain. J Med Chem. 1997;40:1835-1844.
18. 99mTc]TRODAT-1: a novel technetium-99m complex as dopamine transporter imaging agent. Eur J Nucl Med. 1997;24:372-380
19. 99m Tc-TRODAT-1 imaging J Nucl Med. 2001;42:1303-1308.
20. Calne DB, Snow BJ, Lee C. Criteria for diagnosing Parkinson's disease Ann Neurol 1992;32:S125-S127
21. Hoehn MW, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology (Minneap). 1967;17:427-442.
22. 18F] fluoro-L-FDOPA for dopaminergic function imaging with PET. Ann Nucl Med Sci. 1999;12:1-6.
23. Dhawan V, Ma Y, Pillai V, et al. Comparative analysis of striatal FDOPA uptake in Parkinson's disease: ratio method versus graphical approach. J Nucl Med. 2002;43:1324-1330.
24. 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol. 1993;34:423-431.
25. Ishikawa T, Dhawan V, Kazumata K, et al. Comparative nigrostriatal dopaminergic imaging with iodine-123-βCIT-FP SPECT and fluorine-18-FDOPA/ PET. J Nucl Med 1996;37:1760-1765.
26. Aquilonius SM, Bergstrom K, Eckernan SA, et al. In vivo evaluation of striatal dopamine reuptake sites using C-11-nomifensine and PET. Acta Neurol Scand. 1987;76:283-287.
27. Kilbourn MR, Carey JE, Koeppe RA, et al. Biodistribution, dosimetry, metabolism and monkey PET studies of [F-18]GBR 13119 imaging the dopamine uptake system in vivo Nucl Med Biol. 1989;16:569-576.
28. Eidelberg D, Moeller JR, Ishikawa T, et al. Early differential diagnosis of Parkinson's disease with F-18-FDG and PET. Neurology. 1995;45:1995-2004
29. Fischman AJ, Babich JW, Elmaleh DR, et al. SPECT imaging of dopamine transporter sites in normal and MPTP-treated rhesus monkeys. J Nucl Med. 1997;38:144-150
30. 11C]RTI-32 PET studies of the dopamine transporter in early dopamine-naive Parkinson's disease: implications for the symptomatic threshold. Neurology. 1997;48:1578-1583.
31. Tatsch K. Can SPET imaging of dopamine uptake sites replace PET imaging in Parkinson's disease? Eur J Nucl Med. 2002;29:711-714.
32. Stoessl AJ. Neurochemical and neuroreceptor imaging with PET in Parkinson's disease. Adv Neurol. 2001;86:215-223.
33. Lee CS, Samii A, Sossi I, et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol. 2000;47:493-503.
34. Torstenson R, Hartvig P, Langstrom B, Westerberg G, Tedroff J. Differential effects of levodopa on dopaminergic function in early and advanced Parkinson's disease. Ann Neurol. 1997;41:334-340.